Ibrahim Elsayed, Ahmed Hassen Elshafeey, Soad Ali Yehia

Controlled Release Injection of a Central Nervous System Acting Drug

• Broschiertes Buch

Produktbeschreibung

Alzheimer's disease is a chronic, progressive, neurodegenerative disorder of the brain characterized by deficits in memory and cognitive function. Donepezil is a reversible, noncompetitive cholinesterase inhibitor. It has a high binding specificity for brain acetylcholinesterase, with little to no affinity for butyrylcholinesterase. It is approved by the FDA for the treatment of severe Alzheimer's disease. The aim of this work is to formulate depot injection lipospheres and in situ implants containing Donepezil for treatment of Alzheimer disease in order to decrease dosing frequency and increase patient compliance. The work is divided into: Chapter 1: Formulation and In Vitro Evaluation of Injectable Donepezil Lipospheres. Chapter 2: Formulation and In Vitro Evaluation of Injectable Donepezil in Situ Implant. Chapter 3: Comparative Pharmacokinetic Study of Different Injectable Donepezil Formulae.

Produktdetails

• Verlag: LAP Lambert Academic Publishing
• Seitenzahl: 292
• Erscheinungstermin: 6. November 2014
• Englisch
• Abmessung: 220mm x 150mm x 18mm
• Gewicht: 453g
• ISBN-13: 9783659633386
• ISBN-10: 3659633380
• Artikelnr.: 41870871

Autorenporträt

Ibrahim Elsayed is a postdoctoral research associate at the Faculty of Computer Science, University of Vienna. He received his MSc in 2005 from the University of Vienna and his PhD with distinction in 2011 from the Vienna University of Technology, both in Business Informatics.¿¿ ¿